Ablynx Demonstrates Proof-of-Concept by Biomarker For Its Anti-Thrombotic ALX-0081

GHENT, Belgium, 22 December 2009 - Ablynx [Euronext Brussels:
ABLX] announced today detailed results from the open label
extension of the Phase Ib study of its anti-thrombotic, ALX-0081,
in patients with stable angina undergoing percutaneous...